By Colin Kellaher
Inhibikase Therapeutics' chief financial officer, Garth Lees-Rolfe, has resigned from the clinical-stage pharmaceutical company, which has hired David McIntyre as its new finance chief.
Inhibikase on Monday said Lees-Rolfe's resignation after a year in the post wasn't the result of any dispute or disagreement relating to the Atlanta company's operations, policies or practices, adding that he will be entitled to receive severance benefits under a separation agreement.
Inhibikase said McIntyre, 54 years old, previously served as chief financial officer of Anthos Therapeutics. The company said McIntyre will receive an annual base salary of $485,000 and an annual bonus of up to 45% of his base pay.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 14, 2025 08:41 ET (12:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.